Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding. The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, and Quan Capital. The company intends to use the funds to support the advancement of Avenzo’s pipeline of potential best-in-class oncology drug candidates. Led by CEO and President Athena Countouriotis, Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing new oncology therapies for patients. This funding, which follows Avenzo’s $386M Series A/A-1 financing announced in November 2024, brings the total capital raised to $446M.